Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

Grammati Sarri; Wei Liu; Luke Zabotka; Andreas Freitag; Ravinder Claire; Grace Wangge; Jamie Elvidge; Dalia Dawoud; Dimitri Bennett; Xuerong Wen; Xiaojuan Li; Christopher T. Rentsch; Md Jamal Uddin; M. Sanni Ali; Mugdha Gokhale; Anouk Déruaz-Luyet; Daniela C. Moga; Jeff Jianfei Guo; Andrew R. Zullo; Elisabetta Patorno; Kueiyu Joshua Lin

doi:10.1002/cpt.2977

Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

Grammati Sarri, Wei Liu, Luke Zabotka, Andreas Freitag, Ravinder Claire, Grace Wangge, Jamie Elvidge, Dalia Dawoud, Dimitri Bennett, Xuerong Wen, Xiaojuan Li, Christopher T. Rentsch, Md Jamal Uddin, M. Sanni Ali, Mugdha Gokhale, Anouk Déruaz-Luyet, Daniela C. Moga, Jeff Jianfei Guo, Andrew R. Zullo, Elisabetta PatornoKueiyu Joshua Lin

Research output: Contribution to journal › Review article › peer-review

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, the urgency for updated evidence to inform public health and clinical care placed systematic literature reviews (SLRs) at the cornerstone of research. We aimed to summarize evidence on prognostic factors for COVID-19 outcomes through published SLRs and to critically assess quality elements in the findings' interpretation. An umbrella review was conducted via electronic databases from January 2020 to April 2022. All SLRs (and meta-analyses) in English were considered. Data screening and extraction were conducted by two independent reviewers. AMSTAR 2 tool was used to assess SLR quality. The study was registered with PROSPERO (CRD4202232576). Out of 4,564 publications, 171 SLRs were included of which 3 were umbrella reviews. Our primary analysis included 35 SLRs published in 2022, which incorporated studies since the beginning of the pandemic. Consistent findings showed that, for adults, older age, obesity, heart disease, diabetes, and cancer were more strongly predictive of risk of hospitalization, intensive care unit admission, and mortality due to COVID-19. Male sex was associated with higher risk of short-term adverse outcomes, but female sex was associated with higher risk of long COVID. For children, socioeconomic determinants that may unravel COVID-19 disparities were rarely reported. This review highlights key prognostic factors of COVID-19, which can help clinicians and health officers identify high-risk groups for optimal care. Findings can also help optimize confounding adjustment and patient phenotyping in comparative effectiveness research. A living SLR approach may facilitate dissemination of new findings. This paper is endorsed by the International Society for Pharmacoepidemiology.

Original language	English
Pages (from-to)	604-613
Number of pages	10
Journal	Clinical Pharmacology and Therapeutics
Volume	114
Issue number	3
DOIs	https://doi.org/10.1002/cpt.2977
State	Published - Sep 2023

Bibliographical note

Funding Information:
This work was partly funded by ISPE and also received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 806968. The JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Funding Information:
G.S. and A.F. are employed by Cytel, Inc. D.B. is an employee of Takeda. L.Z. and M.S.A. report no declarations. X.L. receives research support from the NIH (R03AG070661 and K01AG073651). A.R.Z. receives grant funding paid directly to Brown University by Sanofi for collaborative research on the epidemiology of infections and vaccinations in nursing home residents and infants. A.R.Z. also receives grant funding from the U.S. National Institute on Aging (R01AG077620 and R01AG065722). E.P. is investigator of a research grant to the Brigham and Women's Hospital from Boehringer‐Ingelheim, not related to the topic of this work. E.P. receives research grants from the Patient Centered Outcomes Research Institute (DB‐2020C2‐20326) and the US Food and Drug Administration (5U01FD007213), not related to the topic of this work. All other authors declared no competing interests for this work.

Publisher Copyright:
© 2023 The Authors. Clinical Pharmacology & Therapeutics © 2023 American Society for Clinical Pharmacology and Therapeutics.

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cpt.2977

Cite this

Sarri, G., Liu, W., Zabotka, L., Freitag, A., Claire, R., Wangge, G., Elvidge, J., Dawoud, D., Bennett, D., Wen, X., Li, X., Rentsch, C. T., Uddin, M. J., Ali, M. S., Gokhale, M., Déruaz-Luyet, A., Moga, D. C., Guo, J. J., Zullo, A. R., ... Lin, K. J. (2023). Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology. Clinical Pharmacology and Therapeutics, 114(3), 604-613. https://doi.org/10.1002/cpt.2977

@article{db8d7fd760064f2f9780b290751487b4,

title = "Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology",

abstract = "During the coronavirus disease 2019 (COVID-19) pandemic, the urgency for updated evidence to inform public health and clinical care placed systematic literature reviews (SLRs) at the cornerstone of research. We aimed to summarize evidence on prognostic factors for COVID-19 outcomes through published SLRs and to critically assess quality elements in the findings' interpretation. An umbrella review was conducted via electronic databases from January 2020 to April 2022. All SLRs (and meta-analyses) in English were considered. Data screening and extraction were conducted by two independent reviewers. AMSTAR 2 tool was used to assess SLR quality. The study was registered with PROSPERO (CRD4202232576). Out of 4,564 publications, 171 SLRs were included of which 3 were umbrella reviews. Our primary analysis included 35 SLRs published in 2022, which incorporated studies since the beginning of the pandemic. Consistent findings showed that, for adults, older age, obesity, heart disease, diabetes, and cancer were more strongly predictive of risk of hospitalization, intensive care unit admission, and mortality due to COVID-19. Male sex was associated with higher risk of short-term adverse outcomes, but female sex was associated with higher risk of long COVID. For children, socioeconomic determinants that may unravel COVID-19 disparities were rarely reported. This review highlights key prognostic factors of COVID-19, which can help clinicians and health officers identify high-risk groups for optimal care. Findings can also help optimize confounding adjustment and patient phenotyping in comparative effectiveness research. A living SLR approach may facilitate dissemination of new findings. This paper is endorsed by the International Society for Pharmacoepidemiology.",

author = "Grammati Sarri and Wei Liu and Luke Zabotka and Andreas Freitag and Ravinder Claire and Grace Wangge and Jamie Elvidge and Dalia Dawoud and Dimitri Bennett and Xuerong Wen and Xiaojuan Li and Rentsch, {Christopher T.} and Uddin, {Md Jamal} and Ali, {M. Sanni} and Mugdha Gokhale and Anouk D{\'e}ruaz-Luyet and Moga, {Daniela C.} and Guo, {Jeff Jianfei} and Zullo, {Andrew R.} and Elisabetta Patorno and Lin, {Kueiyu Joshua}",

note = "Funding Information: This work was partly funded by ISPE and also received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 806968. The JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Funding Information: G.S. and A.F. are employed by Cytel, Inc. D.B. is an employee of Takeda. L.Z. and M.S.A. report no declarations. X.L. receives research support from the NIH (R03AG070661 and K01AG073651). A.R.Z. receives grant funding paid directly to Brown University by Sanofi for collaborative research on the epidemiology of infections and vaccinations in nursing home residents and infants. A.R.Z. also receives grant funding from the U.S. National Institute on Aging (R01AG077620 and R01AG065722). E.P. is investigator of a research grant to the Brigham and Women's Hospital from Boehringer‐Ingelheim, not related to the topic of this work. E.P. receives research grants from the Patient Centered Outcomes Research Institute (DB‐2020C2‐20326) and the US Food and Drug Administration (5U01FD007213), not related to the topic of this work. All other authors declared no competing interests for this work. Publisher Copyright: {\textcopyright} 2023 The Authors. Clinical Pharmacology & Therapeutics {\textcopyright} 2023 American Society for Clinical Pharmacology and Therapeutics.",

year = "2023",

month = sep,

doi = "10.1002/cpt.2977",

language = "English",

volume = "114",

pages = "604--613",

number = "3",

}

Sarri, G, Liu, W, Zabotka, L, Freitag, A, Claire, R, Wangge, G, Elvidge, J, Dawoud, D, Bennett, D, Wen, X, Li, X, Rentsch, CT, Uddin, MJ, Ali, MS, Gokhale, M, Déruaz-Luyet, A, Moga, DC, Guo, JJ, Zullo, AR, Patorno, E & Lin, KJ 2023, 'Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology', Clinical Pharmacology and Therapeutics, vol. 114, no. 3, pp. 604-613. https://doi.org/10.1002/cpt.2977

TY - JOUR

T1 - Prognostic Factors of COVID-19

T2 - An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

AU - Sarri, Grammati

AU - Liu, Wei

AU - Zabotka, Luke

AU - Freitag, Andreas

AU - Claire, Ravinder

AU - Wangge, Grace

AU - Elvidge, Jamie

AU - Dawoud, Dalia

AU - Bennett, Dimitri

AU - Wen, Xuerong

AU - Li, Xiaojuan

AU - Rentsch, Christopher T.

AU - Uddin, Md Jamal

AU - Ali, M. Sanni

AU - Gokhale, Mugdha

AU - Déruaz-Luyet, Anouk

AU - Moga, Daniela C.

AU - Guo, Jeff Jianfei

AU - Zullo, Andrew R.

AU - Patorno, Elisabetta

AU - Lin, Kueiyu Joshua

N1 - Funding Information: This work was partly funded by ISPE and also received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 806968. The JU receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Funding Information: G.S. and A.F. are employed by Cytel, Inc. D.B. is an employee of Takeda. L.Z. and M.S.A. report no declarations. X.L. receives research support from the NIH (R03AG070661 and K01AG073651). A.R.Z. receives grant funding paid directly to Brown University by Sanofi for collaborative research on the epidemiology of infections and vaccinations in nursing home residents and infants. A.R.Z. also receives grant funding from the U.S. National Institute on Aging (R01AG077620 and R01AG065722). E.P. is investigator of a research grant to the Brigham and Women's Hospital from Boehringer‐Ingelheim, not related to the topic of this work. E.P. receives research grants from the Patient Centered Outcomes Research Institute (DB‐2020C2‐20326) and the US Food and Drug Administration (5U01FD007213), not related to the topic of this work. All other authors declared no competing interests for this work. Publisher Copyright: © 2023 The Authors. Clinical Pharmacology & Therapeutics © 2023 American Society for Clinical Pharmacology and Therapeutics.

PY - 2023/9

Y1 - 2023/9

N2 - During the coronavirus disease 2019 (COVID-19) pandemic, the urgency for updated evidence to inform public health and clinical care placed systematic literature reviews (SLRs) at the cornerstone of research. We aimed to summarize evidence on prognostic factors for COVID-19 outcomes through published SLRs and to critically assess quality elements in the findings' interpretation. An umbrella review was conducted via electronic databases from January 2020 to April 2022. All SLRs (and meta-analyses) in English were considered. Data screening and extraction were conducted by two independent reviewers. AMSTAR 2 tool was used to assess SLR quality. The study was registered with PROSPERO (CRD4202232576). Out of 4,564 publications, 171 SLRs were included of which 3 were umbrella reviews. Our primary analysis included 35 SLRs published in 2022, which incorporated studies since the beginning of the pandemic. Consistent findings showed that, for adults, older age, obesity, heart disease, diabetes, and cancer were more strongly predictive of risk of hospitalization, intensive care unit admission, and mortality due to COVID-19. Male sex was associated with higher risk of short-term adverse outcomes, but female sex was associated with higher risk of long COVID. For children, socioeconomic determinants that may unravel COVID-19 disparities were rarely reported. This review highlights key prognostic factors of COVID-19, which can help clinicians and health officers identify high-risk groups for optimal care. Findings can also help optimize confounding adjustment and patient phenotyping in comparative effectiveness research. A living SLR approach may facilitate dissemination of new findings. This paper is endorsed by the International Society for Pharmacoepidemiology.

AB - During the coronavirus disease 2019 (COVID-19) pandemic, the urgency for updated evidence to inform public health and clinical care placed systematic literature reviews (SLRs) at the cornerstone of research. We aimed to summarize evidence on prognostic factors for COVID-19 outcomes through published SLRs and to critically assess quality elements in the findings' interpretation. An umbrella review was conducted via electronic databases from January 2020 to April 2022. All SLRs (and meta-analyses) in English were considered. Data screening and extraction were conducted by two independent reviewers. AMSTAR 2 tool was used to assess SLR quality. The study was registered with PROSPERO (CRD4202232576). Out of 4,564 publications, 171 SLRs were included of which 3 were umbrella reviews. Our primary analysis included 35 SLRs published in 2022, which incorporated studies since the beginning of the pandemic. Consistent findings showed that, for adults, older age, obesity, heart disease, diabetes, and cancer were more strongly predictive of risk of hospitalization, intensive care unit admission, and mortality due to COVID-19. Male sex was associated with higher risk of short-term adverse outcomes, but female sex was associated with higher risk of long COVID. For children, socioeconomic determinants that may unravel COVID-19 disparities were rarely reported. This review highlights key prognostic factors of COVID-19, which can help clinicians and health officers identify high-risk groups for optimal care. Findings can also help optimize confounding adjustment and patient phenotyping in comparative effectiveness research. A living SLR approach may facilitate dissemination of new findings. This paper is endorsed by the International Society for Pharmacoepidemiology.

UR - http://www.scopus.com/inward/record.url?scp=85165288366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85165288366&partnerID=8YFLogxK

U2 - 10.1002/cpt.2977

DO - 10.1002/cpt.2977

M3 - Review article

C2 - 37342987

AN - SCOPUS:85165288366

SN - 0009-9236

VL - 114

SP - 604

EP - 613

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this